Rifabutin

Rifabutin Properties

Melting point	169-171°C
Boiling point	969.6±65.0 °C(Predicted)
Density	1.33±0.1 g/cm3(Predicted)
storage temp.	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility	DMSO: >5mg/mL
form	powder
pka	3.31±0.70(Predicted)
color	Dark Red to Dark Purple
Water Solubility	0.19g/L(temperature not stated)
BCS Class	2
Stability	Hygroscopic and Light Sensitive
InChIKey	ATEBXHFBFRCZMA-VXTBVIBXSA-N
CAS DataBase Reference	72559-06-9

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS07
Signal word	Warning
Hazard statements	H302-H319
Precautionary statements	P305+P351+P338
WGK Germany	3
RTECS	VJ6700000
HS Code	2941906000

Rifabutin price More Price(5)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich(India)	R3530	Rifabutin >98% (HPLC), powder	72559-06-9	5MG	₹10597.68	2022-06-14	Buy
Sigma-Aldrich(India)	R3530	Rifabutin >98% (HPLC), powder	72559-06-9	25MG	₹42661.33	2022-06-14	Buy
Sigma-Aldrich(India)	PHR2611	Rifabutin Pharmaceutical Secondary Standard; Certified Reference Material	72559-06-9	100MG	₹22764.98	2022-06-14	Buy
TCI Chemicals (India)	R0211	Rifabutin	72559-06-9	100MG	₹7200	2022-05-26	Buy
TCI Chemicals (India)	R0211	Rifabutin	72559-06-9	1G	₹18600	2022-05-26	Buy

Product number	Packaging	Price	Buy
R3530	5MG	₹10597.68	Buy
R3530	25MG	₹42661.33	Buy
PHR2611	100MG	₹22764.98	Buy
R0211	100MG	₹7200	Buy
R0211	1G	₹18600	Buy

Rifabutin Chemical Properties,Uses,Production

Description

Rifabutin, a rifamycin antibacterial derivative, is the first agent approved and introduced for the prevention of Mycobacterium avium complex (MAC) in AIDS patients. It is also indicated in combination chemotherapy for the prophylaxis and treatment of MAC infections in HIV positive patients and for newly diagnosed and chronic tuberculosis.

Chemical Properties

Red-Brown Powder

Uses

Rifamycins are antibiotics that inhibit DNA-dependent RNA polymerases and are usually bactericidal against Gram-positive bacteria but bacteriostatic against Gram-negative bacteria. Rifamycins are also effective against Mycobacterium species, including M. tuberculosis. Rifabutin is a broad-spectrum rifamycin antibiotic that has applications against tuberculosis, H. pylori, M. avium complex, Chlamydia, and other bacteria. It is also useful in co-infections with human immunodeficiency virus, including tuberculosis.

Indications

Rifabutin (Mycobutin), an antibiotic related to rifampin, shares its mechanism of action, that is, inhibition of RNA polymerase. Rifabutin has significant activity in vitro and in vivo against M. avium-intracellular complex (MAC) isolates from both HIV-infected and non–HIV-infected individuals. It has better activity against MAC organisms than rifampin. Rifabutin is active against M. tuberculosis, including some rifampinresistant strains, such as M.leprae and M.fortuitum. It has a spectrum of activity against gram-positive and gramnegative organisms similar to that of rifampin. The molecular basis for resistance to rifabutin is shared by both rifampin and rifabutin; this explains the virtually complete cross-resistance that occurs between these drugs.

Antimicrobial activity

The activity is similar to that of rifampicin, but it is more active against the Mycobacterium avium complex (MIC 0.01–2 mg/L) and several other atypical mycobacteria. It inhibits the replication of human immunodeficiency virus 1 (HIV-1) in concentrations (10 mg/L) that are not toxic to lymphoid cells, but no efficacy on HIV infections has been demonstrated.

Acquired resistance

The frequency of spontaneously resistant mutants in several bacterial species, including M. tuberculosis, M. leprae, Staphylococcus aureus and Chlamydia trachomatis, is somewhat lower than with rifampicin.

Pharmaceutical Applications

Rifabutine; ansamycin. Molecular weight: 847.02.
A semisynthetic spiropiperidyl derivative of rifamycin S, available for oral administration. It is slightly soluble in water and soluble in organic solvents.

Pharmacology

Rifabutin is well absorbed orally, and peak plasma concentrations are reached in 2 to 3 hours. Because of its lipophilicity, rifabutin achieves a 5- to 10-fold higher concentration in tissues than in plasma. The drug has a half-life range of 16 to 96 hours and is eliminated in urine and bile.
Rifabutin appears as effective as rifampin in the treatment of drug-susceptible tuberculosis and is used in the treatment of latent tuberculosis infection either alone or in combination with pyrazinamide. Clinical use of rifabutin has increased in recent years, especially in the treatment of HIV infection. It is a less potent inducer of cytochrome 450 enzymes pathways than rifampin and results in less drug interaction with the protease inhibitors and nonnucleoside reverse transcriptase inhibitors. Rifabutin is therefore commonly substituted for rifampin in the treatment of tuberculosis in HIV-infected patients. Another important use of rifabutin in the HIV-infected population is prevention and treatment of disseminated MAC.

Pharmacokinetics

Oral absorption：12–20%
C_max 300 mg oral ：0.38 mg/L after 3.3 h
Plasma half-life：16 h
Volume of distribution：9.3 L/kg
Plasma protein binding： 85%
absorption and distribution
Oral absorption is rapid but incomplete, with considerable interpatient variation. It is well distributed, concentrations in many organs being higher than that in plasma. The average concentration in lungs is 6.5 times the simultaneous plasma concentration.
Metabolism and excretion
Rifabutin is mainly metabolized to the active desacetyl derivative, although several other oxidation products have been detected in urine, where some 10% of the dose is eliminated. About 30–50% of the dose can be recovered from the feces. Elimination from plasma is biphasic, with a terminal half-life of 45 h. The drug is a weak inducer of hepatic enzymes. The rate of metabolism increases, and the plasma area under the concentration–time curve (AUC) declines as the treatment continues.

Clinical Use

Prevention of infections with M. avium complex in AIDS patients
Treatment of non-tuberculous mycobacterial disease (in combination with other agents)
Rifabutin in combination with other agents has been proposed as a rescue therapy after Helicobacter pylori treatment failures.Although some efficacy has been observed in the treatment of tuberculosis, its use for this condition is not recommended.

Side effects

The adverse effects that most frequently result in discontinuation of rifabutin include GI intolerance, rash, and neutropenia. Rifabutin levels will be increased with concurrent administration of fluconazole and clarithromycin, resulting in anterior uveitis, polymyalgia syndrome, and a yellowish-tan discoloration of the skin (pseudojaundice). Other adverse reactions are similar to those of rifampin, such as hepatitis, red-orange discoloration of body fluids, and drug interactions due to effects on the hepatic P450 cytochrome enzyme system.

Rifabutin Preparation Products And Raw materials

Raw materials

4,4-Piperidinediol hydrochloride

Preparation Products

Rifabutin Suppliers

Global( 321)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
Lupin Ltd	+91-8019896181 +91-8019896181	Maharashtra, India	93	58	Inquiry
Shivam Pharma Chemicals	91-22-26403900	Maharashtra, India	656	58	Inquiry
CLEARSYNTH LABS LTD.	+91-22-45045900	Hyderabad, India	6351	58	Inquiry
A.J Chemicals	91-9810153283	New Delhi, India	6124	58	Inquiry
TCI Chemicals (India) Pvt. Ltd.	1800 425 7889	New Delhi, India	6778	58	Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd	+91-172-5066494	Haryana, India	6773	58	Inquiry
SynZeal Research Pvt Ltd	+1 226-802-2078	Gujarat, India	6522	58	Inquiry
LUPIN LTD	+91 124 4885000 / +91 124 3325000	New Delhi, India	191	58	Inquiry
Vinayak Group	91-79-40321603	Gujarat, India	36	58	Inquiry
Indogulf Group	91-22-23455220	Maharashtra, India	249	58	Inquiry

Supplier	Advantage
Lupin Ltd	58
Shivam Pharma Chemicals	58
CLEARSYNTH LABS LTD.	58
A.J Chemicals	58
TCI Chemicals (India) Pvt. Ltd.	58
Pharmaffiliates Analytics and Synthetics P. Ltd	58
SynZeal Research Pvt Ltd	58
LUPIN LTD	58
Vinayak Group	58
Indogulf Group	58

Rifabutin Spectrum

Rifabutin(72559-06-9)¹HNMR

72559-06-9(Rifabutin)Related Search:

Rifapentine Rifamycin Sodium RIFAMYCIN SV Rimsulfuron Regorafenib

Rhodium 2-(4-BIPHENYL)ETHYLAMINE 5-ACETYL-2,3-DIHYDROBENZO(B)FURAN 3-Amino-4-imino-rifamycin S 2,3-Dihydrobenzo[b]furan-5-carbaldehyde

2,3-DIMETHYLANISALDEHYDE 3,3-Dimethoxybutan-2-one PHENYLGLYOXAL MONOHYDRATE 2-Amino-4'-methoxyacetophenone 2,5-DIMETHYLPHENETHYLAMINE

RIFAMYCIN 1-(4-HYDROXY-2,5-DIMETHYL-PHENYL)-ETHANONE 25-O-Deacetyl Rifabutin,25-DESACETYL RIFABUTIN

chevron_left

1of4

chevron_right

4-Deoxw3，4-[2-spiro(N-isobutyl-4-pipendyl)]-(1H)-imidazo-(2，5-dihydro)rifamycin S 4-N-ISOBUTYLSPIROPIPERIDYLRIFAMYCIN S RIFABUTIN 1,4-dihydro-1-deoxy-1’,4-didehydro-5’-(2-methylpropyl)-1-oxo-rifamycinxi (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-hepta-methyl-spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo-[2',3':7,8]-naphth[1,2-d]imidazol-2,4'-piperidin]-5,10,26-(3H,9H)-trione Ansatipine Mycobutin (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro(9,4-(epoxypentadeca(1,11,13)trienimino)-2H-furo(2',3':7,8)naphth(1,2-d)imidazole-2,4'-piperidine)-5,10,26(3H,9H)-trione,16-acetate 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxo 1',4-Didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxorifamycin XIV Rifabatin Ansamycin (Rifabutin) Rifabutin (50 mg) Collagen proline hydroxylase inhycobutin (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione 1,4-dihydro-1-deoxy-1’,4-didehydro-5’-(2-methylpropyl)-1-oxorifamycinxiv 1’,4-Didehydro-1-deoxy-1,4-dihydro-5’-(2-methylpropyl)-1-oxo- 4-deoxo-3,4-(2-spiro(n-isobutyl-4-piperidyl)-2,5-dihydro-1h-imidazo)-rifamyc antibioticlm427 lm427 Ansatipine (Farmitalia) Mycobutin (Farmitalia) RIFABUTINE(LM－427、ANSAMYCIN、ANSATIPIN、ANSMYCIN、MYCOBUTIN):4-N-ISOBUTYLSPIROPIPERIDYLRIFAMYCIN S Rifamycin XIV, Ansamycin, Rifabutin (Ansamycin) (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidaz MYCOBUTIN; ANSAMYCIN; LM 427; ANSATIPINE Rifabutin (Mycobutin) Rifabutin CRS Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione,16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-,[9S-(9R*,12E,14R*,15S*,16R*,17S* Rifabutin USP/EP/BP Rifabutin Impurity (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-(Acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1′-(2-methylpropyl)spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2′,3′:7,8]naphth[1,2-d]imidazole-2,4′-piperidine]-5,10,26 RifabutinQ: What is Rifabutin Q: What is the CAS Number of Rifabutin Q: What is the storage condition of Rifabutin Q: What are the applications of Rifabutin Rifabutin (1603800) RIFABUTINE Rifabutin-d7 Ansamycin Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-, (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)- Levofloxacin D7 Rifabutin (LM427) Rifabutin Impurity 13 Levobutin Lifu pudding 72559-06-9 C46H62N4O11 Intermediates & Fine Chemicals Pharmaceuticals Mycobutin API Chiral Reagents Heterocycles Active Pharmaceutical Ingredients 72559-06-9